NCT07159737: HYBRID MAIN

Comparison of HYBRID Versus Two-Stent Strategies in Unprotected True Left MAIN Bifurcation

Not yet recruiting NA Last updated 30 December 2025

What this trial tests

NA trial testing Two-stent strategy in Unprotected Left Main Coronary Artery Disease in 800 participants. Not yet recruiting.

Timeline

1 January 2026

Primary endpoint
1 January 2028

1 January 2030

Quick facts

Lead sponsor	Hospital Sultanah Bahiyah
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	800
Start date	1 January 2026
Primary completion	1 January 2028
Estimated completion	1 January 2030

Drugs / interventions tested

• Two-stent strategy
• Hybrid Strategy

Conditions studied

• Unprotected Left Main Coronary Artery Disease — all drugs for Unprotected Left Main Coronary Artery Disease →

Sponsor

Hospital Sultanah Bahiyah

Who can join

18 and older, any sex, with Unprotected Left Main Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The number of deaths from heart disease is rising globally, particularly in developing countries. This condition involves the narrowing of arteries that supply blood to the heart. The most critical narrowing occurs in the left main coronary artery (LMCA), which supplies blood to over two-thirds of the heart muscle. Treating this narrowing is essential to prevent heart attacks or death. The LMCA divides into two branches, known as a bifurcation, both of which require treatment if narrowed.

Currently, narrowing in both branches-the left anterior descending artery (LAD) and the left circumflex artery (LCx)-is treated with a two-stent strategy, where metallic stents are placed in each branch to keep the arteries open. However, this approach is prone to re-narrowing, particularly at the origin of the LCx. A new procedure, called the hybrid strategy, offers an alternative. It involves placing one stent in the LMCA and LAD while inflating a special balloon in the LCX. This balloon, known as a drug-coated balloon, releases a chemical that reduces narrowing over time without needing a stent. At present, there is uncertainty which strategy is better. This study will assess whether the hybrid strategy is more effective than the two-stent strategy in preventing death, heart attacks, and re-narrowing of the arteries.

Participants will have an equal chance of receiving either the two-stent or hybrid strategy and will only join the study if their doctor is unsure which method is best. To minimise the burden on participants, all study procedures and follow-ups will be integrated into standard routine care.

The results of this study have the potential to offer a new, safer treatment that could save the lives of millions of people with this condition.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.